The Fort Worth Press - MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

USD -
AED 3.6725
AFN 64.498045
ALL 82.224051
AMD 357.911109
ANG 1.790403
AOA 917.999992
ARS 1552.245042
AUD 1.487498
AWG 1.8
AZN 1.701568
BAM 1.778889
BBD 2.013452
BDT 124.862431
BGN 1.77347
BHD 0.377187
BIF 3006.125762
BMD 1
BND 1.288366
BOB 11.661285
BRL 5.778103
BSD 0.999695
BTN 93.389482
BWP 13.993424
BYN 3.000114
BYR 19600
BZD 2.010633
CAD 1.430865
CDF 2294.000592
CHF 0.840555
CLF 0.025261
CLP 994.190035
CNY 6.66615
CNH 6.66805
COP 3309.02
CRC 445.311541
CUC 1
CUP 23.992906
CVE 100.292423
CZK 22.169932
DJF 178.024567
DKK 6.80141
DOP 60.539085
DZD 137.094024
EGP 53.720858
ERN 15
ETB 164.079674
EUR 0.90995
FJD 2.297898
FKP 0.756582
GBP 0.757725
GEL 2.590255
GGP 0.756582
GHS 11.730947
GIP 0.756582
GMD 74.000173
GNF 8857.115571
GTQ 7.640288
GYD 209.05242
HKD 7.845155
HNL 26.876953
HRK 6.831965
HTG 130.972791
HUF 333.799019
IDR 18254
ILS 3.254645
IMP 0.756582
INR 93.45245
IQD 1515.562185
IRR 1929053.503608
ISK 124.48026
JEP 0.756582
JMD 158.860526
JOD 0.709026
JPY 159.414008
KES 129.990105
KGS 87.449026
KHR 4078.347196
KMF 448.000085
KPW 900.00035
KRW 1329.397181
KWD 0.31169
KYD 0.833136
KZT 443.84516
LAK 22515.803356
LBP 89525.524706
LKR 332.648142
LRD 167.946083
LSL 16.912988
LTL 2.95274
LVL 0.60489
LYD 6.460474
MAD 9.977716
MDL 18.305023
MGA 4547.687046
MKD 56.015616
MMK 2099.387164
MNT 3606.75335
MOP 8.079605
MRU 40.508252
MUR 47.860043
MVR 15.433829
MWK 1733.487348
MXN 18.45096
MYR 4.098963
MZN 63.907732
NAD 16.912757
NGN 1350.869856
NIO 36.790956
NOK 9.637045
NPR 149.424033
NZD 1.82065
OMR 0.384524
PAB 0.999682
PEN 3.414253
PGK 4.497642
PHP 63.574997
PKR 276.397058
PLN 4.00875
PYG 6228.540504
QAR 3.644326
RON 4.867103
RSD 107.038986
RUB 82.204134
RWF 1479.544504
SAR 3.760904
SBD 8.137041
SCR 13.8922
SDG 601.498572
SEK 10.13571
SGD 1.289235
SHP 0.757117
SLE 22.801691
SLL 20969.503664
SOS 571.283045
SRD 37.437963
STD 20697.981008
STN 22.283565
SVC 8.747021
SYP 13002.000337
SZL 16.91126
THB 33.8665
TJS 9.212201
TMT 3.5
TND 3.02519
TOP 2.40776
TRY 50.441697
TTD 6.768777
TWD 32.958011
TZS 2650.003017
UAH 45.318338
UGX 4148.305798
UYU 40.61103
UZS 12014.188913
VES 915.501901
VND 25687
VUV 121.064676
WST 2.823281
XAF 596.887869
XAG 0.021752
XAU 0.0002631714
XCD 2.70255
XCG 1.801703
XDR 0.707052
XOF 596.887869
XPF 108.472418
YER 236.550078
ZAR 16.95717
ZMK 9001.196037
ZMW 20.479237
ZWL 321.999592
SSP 5928.707524
MXV 2.06991
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

Backed by a Strong Balance Sheet, MIRA Accelerates Toward Becoming a Clinical-Stage Company and Advancing Breakthroughs in Pain and Depression Treatment

Text size:

Backed by a Strong Balance Sheet, MIRA Accelerates Toward Becoming a Clinical-Stage Company and Advancing Breakthroughs in Pain and Depression Treatment

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company, is pleased to announce the selection of The Centre for Human Drug Research (CHDR) in Leiden, The Netherlands, as the site for its Phase I/IIa clinical trial of Ketamir-2, a novel oral ketamine analog. Recruitment for the trial is set to begin in Q1 2025, with initial safety and efficacy results from the Phase I study in healthy subjects expected in the second half of 2025. The Phase IIa study, planned to start in Q4 2025, will focus on diabetic neuropathy patients, with initial human efficacy results anticipated in the first half of 2026.

The trial leverages CHDR's proprietary PainCart® technology, a validated tool for measuring pain response. This advanced technology allows MIRA to assess early signs of efficacy in healthy subjects during Phase I, a capability that is typically unavailable at this stage of development. Psychoactivity assessments will also be conducted separately as part of an independent evaluation. The unique capabilities of PainCart® was a key reason for selecting CHDR as the trial site, allowing MIRA to gain valuable insights into Ketamir-2's potential for pain management earlier in the clinical process together with information about safety and pharmacokinetics.

Innovative Study Design Focused on Early Proof-of-Concept Data

The Phase I/IIa trial is structured as a randomized, double-blind, placebo-controlled study conducted in two parts:

Phase I: Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts in healthy subjects will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics. PainCart will be used to measure pain response, providing robust early efficacy data, while psychoactivity will be assessed separately through dedicated testing.

Phase IIa: The Proof of Concept (POC) study, planned to begin in the last quarter of 2025, will focus on diabetic neuropathy patients, generating efficacy data in a patient population to validate the Phase I findings.

"This innovative protocol is designed to deliver early, robust proof-of-concept data, advancing Ketamir-2's clinical development and positioning us for strategic partnerships or an M&A opportunity," said Erez Aminov, CEO and Chairman of MIRA Pharmaceuticals.

Dr. Itzchak Angel, Chief Scientific Advisor at MIRA Pharmaceuticals, stated, "the selection of CHDR and the incorporation of PainCart technology in this trial represent a significant step forward in Ketamir-2's development. The ability to gather early efficacy data in healthy subjects provides an invaluable opportunity to optimize the drug's potential and streamline its progress toward addressing the unmet needs in pain management. Our goal is to establish Ketamir-2 as a pioneering therapy in this space."

Ongoing Preclinical and Manufacturing Updates

MIRA continues to make significant progress in its broader pipeline. Preclinical studies for diabetic neuropathy and PTSD are ongoing, and the Company remains on track to complete its IND submission by year-end. Capsule manufacturing for the Phase I/IIa trial is also in its final stages, ensuring readiness for patient dosing in early 2025.

The Company is actively pursuing non-dilutive grant opportunities to support its research programs and is preparing multiple scientific journal publications detailing Ketamir-2's mechanism of action, preclinical results, and potential therapeutic applications. These efforts aim to enhance scientific understanding and attract additional resources for development.

Strong Financial Position and Strategic Focus

MIRA believes that it has a healthy balance sheet, and accordingly, is well-positioned to achieve its strategic goals without reliance on unfavorable financing deals. "We are committed to diligently pursuing strategic partnerships and ensuring the successful development of Ketamir-2 while exploring its potential for broader market applications," added Aminov.

Superior Efficacy and Safety: A Groundbreaking Therapy

Ketamir-2 has consistently outperformed several well-known drugs like pregabalin and gabapentin in preclinical studies, demonstrating superior efficacy and a strong safety profile. The drug is designed to address an urgent unmet need for safe, effective, and non-addictive treatments for pain and depression.

"Our focus on developing a non-addictive, safe, and highly effective solution for pain and depression addresses an urgent unmet need," said Aminov. "With no side effects observed to date, Ketamir-2 represents a promising breakthrough in pain management."

Looking Ahead

As MIRA transitions into a clinical-stage company, the team remains dedicated to advancing Ketamir-2 through rigorous clinical trials, building strategic partnerships, and exploring additional indications to maximize its therapeutic potential. MIRA will aim to achieve significant milestones in the months ahead as it continues to generate innovation in pain and depression treatment.

For more information, please visit www.mirapharmaceuticals.com

Cautionary Note Regarding Forward-Looking Statements

This press release and the statements of MIRA Pharmaceuticals' (or the "Company") management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. These forward-looking statements include, without limitation, statements regarding the anticipated benefits of the study results described herein as well as the timing for the Company's other preclinical studies and the filing of an IND for Ketamir-2. Any forward-looking statements in this press release are based on the Company's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond the Company's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning the Company's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2023, and other SEC filings, which are on file with the SEC at www.sec.gov and the Company's website at https://www.mirapharmaceuticals.com/investors/sec-filings. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Helga Moya
[email protected]
(786) 432-9792

SOURCE: MIRA Pharmaceuticals

S.Jones--TFWP